今日提示 北交所新股海菲曼（申购代码：920183）今日申购，发行价为19.71元/股 新一轮成品油调价窗口将于今日24时开启 苹果将于太平洋时间2月24日8时举行股东大会 重要新闻提示 智平方宣布完成B轮融资，估值超100亿元；宇树科技机器人集群天坛表演武术视频走红 前沿生物：与葛兰素史克达成独家授权许可协议，将获4000万美元首付款和1300万美元近期里程碑付 款，还将额外获最高9.5亿美元里程碑付款 2026年春节档档期总票房为57.49亿元，《飞驰人生3》成2026年春节档票房冠军 ...

Core Viewpoint - The company, Immune-Onc Therapeutics, is set to present the latest efficacy and safety results of its investigational B7H3 antibody-drug conjugate, DB-1311/BNT324, for treating previously treated metastatic castration-resistant prostate cancer (mCRPC) patients at the 2026 ASCO GU Cancer Symposium [1]. Group 1: Study Overview - The 1/2 phase study (NCT05914116) involves a dose-optimization cohort where mCRPC patients previously treated received DB-1311/BNT324 at doses of 6 mg/kg or 9 mg/kg every three weeks [1]. - In the dose-expansion cohort, patients who had received Lu 177 treatment and those who had not received taxane therapy were administered 6 mg/kg every three weeks until disease progression or intolerable toxicity occurred [1]. Group 2: Patient Demographics and Treatment Outcomes - As of September 5, 2025, 104 mCRPC patients had received DB-1311/BNT324 treatment, with a median follow-up of 9.2 months; 50% of patients remained on treatment [2]. - The median age of patients was 70 years, with a majority being white (53%), followed by Asian (31%) and Black (13%); the median number of prior treatments was 4 [2]. - Among 58 patients eligible for tumor response assessment, the unconfirmed objective response rate was 41.4%, and the confirmed objective response rate was 34.5%, with a disease control rate of 87.9% [2]. Group 3: Progression-Free Survival and Overall Survival - In 82 patients evaluable for radiographic progression-free survival (rPFS), the median rPFS was 11.3 months, with 6-month and 9-month rPFS rates of 72.0% and 63.0%, respectively [2]. - Overall survival (OS) data was not yet mature, but the 6-month and 9-month OS rates were reported at 91.7% and 88.2% [3]. Group 4: Safety Profile - The safety profile was consistent with previous reports, with the most common adverse events being nausea and hematological events, primarily grade 1-2 [3]. - Among the 104 patients, 34 (33%) had previously received Lu 177 treatment, with similar outcomes observed between those who had and had not received Lu 177, although the PSA duration of response was shorter in the former group [3].

每经AI快讯，2月23日，癌症细胞疗法公司Arcellx高开78%，创美国IPO以来最大盘中涨幅，吉利德科学 将以每股115美元的价格收购该公司。 ...

Summary of MoonLake Immunotherapeutics Investor Day Company Overview - **Company Name**: MoonLake Immunotherapeutics - **Founded**: 2021 in Switzerland - **Public Listing**: Nasdaq, went public in April 2022 - **Focus**: Development and commercialization of sonelokimab (SLK), a tri-specific IL-17A and IL-17F inhibiting nanobody targeting large indications in inflammation - **Financial Position**: Well-funded with cash runway into the second half of 2027 and access to a debt facility of up to $400 million [2][3] Product and Clinical Development - **Product**: Sonelokimab (SLK) - **Type**: Nanobody, smaller than traditional antibodies (40 kDa vs. 140-150 kDa) - **Administration**: Subcutaneous injection, 1 mL monthly dosing - **Clinical Trials**: Conducted Phase II and III studies across five large indications in dermatology and rheumatology, including: - Hidradenitis Suppurativa (HS) - Psoriasis (PSO) - Psoriatic Arthritis (PsA) - Axial Spondyloarthritis (axSpA) - **Regulatory Plans**: BLA submission for SLK expected in the second half of 2026, with potential first approval in the US in the second half of 2027 [3][10] Clinical Data Highlights - **S-OLARIS Trial**: Focused on axSpA, showing promising results with high response rates: - Over 80% of patients achieved ASAS40 response by week 8, maintaining high levels by week 12 [17][19] - Significant reduction in bone inflammation measured by SPARCC MRI score, with over 80% reduction observed [20] - Use of innovative imaging techniques (MRI, PET) to assess treatment effects on ossification [21][22] - **Long-term Data**: VELA studies in HS patients show high response rates, with VELA-1 and VELA-2 trials demonstrating competitive efficacy compared to other commercialized drugs [56][57] Market Opportunity - **AxSpA Market**: Estimated market size of $10 billion to $15 billion by 2038, with a conservative growth rate of biologic usage [13] - **HS Market**: Ongoing discussions with the FDA to ensure a competitive label for SLK, leveraging data from VELA studies [25][26] Regulatory Strategy - **FDA Interactions**: Positive feedback received, confirming that no additional clinical trials are required for BLA submission [30][31] - **Label Development**: Focus on establishing substantial evidence of effectiveness (SEE) through VELA-1, VELA-2, and MIRA trials [30][35] - **Competitive Edge**: Emphasis on a clean safety profile and a more convenient dosing regimen compared to competitors [53][54] Key Takeaways - **Innovative Approach**: SLK aims to provide disease modification in axSpA, addressing core disease pathways rather than just symptoms [22][24] - **Strong Clinical Profile**: High response rates and innovative trial designs position SLK favorably against competitors in the IL-17 space [24][52] - **Regulatory Clarity**: Clear guidance from the FDA supports a streamlined path for BLA submission, enhancing investor confidence [35][52] This summary encapsulates the key points discussed during the MoonLake Immunotherapeutics Investor Day, highlighting the company's strategic direction, product development, and market potential.

Group 1 - Gilead Sciences announced a proposed acquisition of cancer cell therapy company Arcellx for $7.8 billion [1] - Following the announcement, Arcellx's stock price surged nearly 80% [1] - Gilead's Kite Pharma previously collaborated with Arcellx to develop and market an experimental CAR-T therapy for multiple myeloma [1]

Core Insights - Frontier Biotech has signed an exclusive licensing agreement with GlaxoSmithKline (GSK) for two small nucleic acid pipeline products, marking a significant step in its globalization strategy [1][2] - The collaboration is expected to enhance GSK's immunology pipeline and provide important opportunities for improving outcomes in various kidney disease patients [2] Financial Aspects - Frontier Biotech will receive an upfront payment of $40 million and a milestone payment of $13 million, with potential additional payments of up to $950 million based on successful development, regulatory, and commercialization milestones [3] - The agreement is anticipated to significantly improve the company's cash flow and optimize its financial structure, providing solid funding support for core pipeline research and technology platform upgrades [3] Development Responsibilities - Frontier Biotech will handle early development work for the two small nucleic acid products, including advancing one product through Phase I clinical trials in China and supporting IND research for the other [1] - GSK will take charge of all global clinical development, regulatory submissions, and commercialization activities for both products [1][2] Market Potential - Small nucleic acid drugs are a key development direction in the global pharmaceutical field, with the potential to address traditional drug limitations and expand into chronic disease areas [2] - The collaboration with GSK is expected to accelerate the international value transformation of Frontier Biotech's pipeline and lay a solid foundation for future commercialization and global partnerships [2][3]

Industry Policy and Environment - The core patent for Semaglutide is set to expire after March 2026, leading to increased market competition, with Jiuyuan Gene being one of the companies applying for this product [1] Product Development Progress - The clinical trial application for the innovative drug JY54 injection (a long-acting insulin analog) was accepted on February 9, 2026, aimed at weight management for obese or overweight populations, with subsequent trial initiation and data disclosure being noteworthy [1] Funding Movements - The company has been actively repurchasing shares since January 2026, including the repurchase of 854,000 shares on February 5 at a cost of 8.7731 million HKD, which may reflect management's outlook on business prospects [2]

Core Viewpoint - Frontier Biotech (688221) has entered into an exclusive licensing agreement with GlaxoSmithKline (GSK) for two small interfering RNA (siRNA) pipeline products, marking a significant collaboration in the biopharmaceutical sector [1] Group 1: Agreement Details - GSK will obtain exclusive rights for the global development, manufacturing, and commercialization of two siRNA products, one of which is in the Investigational New Drug (IND) application stage, while the other is a preclinical candidate [1] - Frontier Biotech will receive an upfront payment of $40 million and a near-term milestone payment of $13 million [1] - The company could earn up to $950 million in additional milestone payments based on successful development, regulatory approval, and commercialization of the two projects [1] Group 2: Financial Implications - Frontier Biotech will also receive tiered royalties on the global net sales of both products, enhancing its revenue potential from this partnership [1]

Core Insights - The first batch of stem cell-based therapeutic products is set to be launched, potentially offering functional cures for previously hard-to-treat major diseases such as Parkinson's disease and heart failure [1] Group 1: Stem Cell Therapy Developments - The Japanese Ministry of Health has approved two stem cell therapy products, one for Parkinson's disease from Sumitomo Pharma and another from Cuorips for severe heart failure, with both expected to be available soon [2] - Stem cell therapy utilizes induced pluripotent stem cells (iPS) to cultivate cells for treating diseases, a breakthrough recognized by the Nobel Prize awarded to Shinya Yamanaka in 2012 [2] - The heart muscle cell patch acts like a "band-aid" for the damaged heart, enhancing the survival rate of the "regeneration seeds" and promoting blood vessel regeneration [2] Group 2: Challenges and Future Prospects - Despite the upcoming market entry of these therapies, high costs associated with stem cell cultivation and regulatory challenges remain significant hurdles [2] - The approval of these therapies is seen as a major benefit for the regenerative medicine sector, potentially advancing foundational research and paving the way for more precise and minimally invasive treatments [3] Group 3: China's Stem Cell Research Landscape - China is rapidly advancing in regenerative medicine, with over 200 stem cell therapy products having received clinical trial approvals as of last year [4] - The new regulations set to take effect in May 2026 will provide clearer pathways for the clinical application of biomedical technologies, including stem cells [4] - There have been multiple successful cases of stem cell treatments for Parkinson's disease in China, indicating significant progress in this field [5]

Core Viewpoint - The company has entered into an exclusive licensing agreement with GlaxoSmithKline (GSK) for two small nucleic acid (siRNA) pipeline products, enhancing its financial position and international recognition in drug development [1][2] Financial Impact - The agreement includes an upfront payment of $40 million and a near-term milestone payment of $13 million, which will improve the company's cash flow and financial structure [1][2] - The company could receive up to $950 million in additional milestone payments based on successful development, regulatory, and commercialization achievements [1][2] Development Responsibilities - The company will be responsible for early development work on the two products, including advancing one product through Phase I clinical trials in China and completing supportive research for the other product's IND [1] - GSK will handle all subsequent global clinical development, regulatory submissions, and commercialization activities for both products [1] Strategic Benefits - The tiered royalty arrangement based on net sales allows the company to share in the future commercial success of the products, creating a potential long-term revenue source [2] - The collaboration with a leading biopharmaceutical company like GSK highlights the company's technical strength and platform value in the small nucleic acid drug development field, gaining international market recognition [2] - This partnership will leverage GSK's resources and experience in global clinical development and commercialization, accelerating the international value transformation of the company's pipeline [2]